Inventiva Invites Investors and Analysts for Insightful Event
Overview of the Upcoming Analyst and Investor Event
Inventiva, a dynamic biopharmaceutical company focused on innovative treatments, has announced an exciting opportunity for investors and analysts. They will be hosting an event that promises to shed light on the company’s strategic direction and significant developments in the realm of metabolic dysfunction-associated steatohepatitis, or MASH. This event is not just an update but a detailed look at the future of treatment options in this area.
Details of the Event
The event is scheduled to take place in New York City on a Wednesday afternoon, from 11:30 AM to 2:00 PM ET. Attendees will have the chance to participate in person or tune in via a live webcast. This hybrid model allows for wider participation, enabling anyone interested in the company's progress to join in. The presentation will outline key updates especially aimed at informing stakeholders about lanifibranor, the company’s flagship asset.
Agenda Highlights
This event will not just be a straightforward update. Attendees can expect a well-rounded agenda that includes:
- An exploration of lanifibranor's positioning in a rapidly expanding global market
- A detailed analysis of its mechanism of action along with clinical evidence gathered from previous trials
- Insights into the ongoing Phase 3 study, including a progress update and patient baseline characteristics
- An examination of how lanifibranor's unique dual action addresses critical needs in the treatment of MASH
Expert Insights
Inventiva is committed to providing the best perspectives in the field by featuring presentations from preeminent voices in the MASH landscape. Among the speakers are:
1. Dr. Nezam Afdhal, a leading figure in gastroenterology and hepatology from Harvard Medical School,
2. Dr. William Alazawi, a prominent hepatologist and research director at Queen Mary University of London,
3. Henry E. Chang, executive director at the Fatty Liver Foundation,
4. Dr. Arun Sanyal, a key opinion leader and co-principal investigator for the Phase 3 NATiV3 study.
How to Participate
For those eager to learn more and participate in this pivotal event, registration is straightforward. Interested parties can sign up for the live webcast on the Inventiva website. A recorded version will also be available to facilitate access to the valuable insights shared during the event.
About Inventiva
Inventiva is passionately focused on addressing significant health challenges through innovative biopharmaceutical advancements. They are primarily dedicated to developing oral small molecule therapies aimed at treating MASH, a chronic liver condition which is becoming increasingly common. The company's lead product, lanifibranor, is currently in critical phases of clinical testing, demonstrating a commitment to improving patient outcomes in this challenging disease area. As it stands, Inventiva is publicly traded on markets includingNASDAQ under the ticker symbol IVA.
Contact Information
For further inquiries regarding the event or the company’s developments, stakeholders can reach out through the following contacts:
- Pascaline Clerc
EVP, Strategy and Corporate Affairs
media@inventivapharma.com
+1 202 499 8937 - ICR Healthcare
Alexis Feinberg
Media Relations
inventivapr@icrhealthcare.com
+1 203 939 2225 - ICR Healthcare
Patricia L. Bank
Investor Relations
patti.bank@icrhealthcare.com
+1 415 513 1284
Frequently Asked Questions
What is the focus of Inventiva's upcoming event?
The event will provide updates on Inventiva's lead asset, lanifibranor, and discuss developments in the treatment of MASH.
Where will the event take place?
The event will be held in New York City and will also be accessible through a live webcast.
Who are the key speakers at the event?
Notable speakers include Dr. Nezam Afdhal, Dr. William Alazawi, Henry E. Chang, and Dr. Arun Sanyal.
How can I participate in the event?
Participants can register for the event on the Inventiva website to join the live webcast or watch a replay afterward.
What is MASH?
MASH, or metabolic dysfunction-associated steatohepatitis, is a progressive liver disease linked to metabolic disorders, which Inventiva aims to treat with its therapies.
About The Author
Contact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.